Scheușan, Alvogen: I have no argument for building a plant from scratch

Laurențiu Scheușan, who has been recently appointed as head over a seven-country region with Alvogen US drug maker, says Romania has become a regional centre for the company, meaning the activity in this area will be coordinated from the domestic market.

Last year, the first operational year for the company in Romania, turnover hit 1.9m dollars, while for this year the target was raised to 6m dollars.
Scheușan wants Romanian turnover to reach 35-30m dollars in 2015.
“There will be organic growth, but as competition is very tight at present, if we want to grow we must also consider acquisitions. However, there will not be large acquisitions and we target medium-sized companies. In Romania, I looked (to buy a company), but I haven’t found any opportunity to present to the board,” Scheușan, sales executive vice-president in CEE with Alvogen, told ZF.
“(…) Unfortunately, I have no argument to present to the board for a greenfield investment in Romania (…),” Scheușan said.